



September 12, 2022

RE: Reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs

To the Honorable Members of Ohio's Congressional Delegation,

We, the undersigned Ohio business leaders and Ohio life science stakeholders, are respectfully writing to share our support for the reauthorization of the SBIR/STTR program before the current funding expires on September 30.

Since its inception in 1982, the SBIR/STTR program has supported our small business community as we work to improve health, develop new agricultural techniques, innovate for our national defense, explore space, and more. Across the agencies that participate in this essential program, Ohio small businesses have received nearly 5,700 awards generating over \$2 billion in funding for research programs intended to meet the needs of these agencies, our country, and our people.

Since the last SBIR/STTR reauthorization in 2016, Ohio small businesses have received more than 1,420 awards totaling over \$646 million.

The SBIR 3.2% set aside and the STTR 0.45% set aside makes it possible for small, entrepreneurial firms to contribute their innovation talents to address the defined needs of these agencies. The SBIR/STTR programs ensure that small businesses have the opportunity to be part of our country's research and development enterprise.

Based on a review of Ohio-specific 2017-21 SBIR/STTR awards, our small business community's highest award concentrations are with the following agencies:

- Department of Defense (61%)
- Health & Human Services (15%)
- Department of Energy (14%)
- NASA (6%)
- National Science Foundation (3%)

While many of these R&D programs are components that support larger agency program requirements, Ohioans' work on life science-related programs illustrates projects that are designed to directly impact some of our most significant health challenges.

Since 2000, over \$532 million, 26% of the state total, has been awarded to life science-related innovation projects in Ohio. Some examples of these developing health innovations include:

- **ASAKE Biotechnology** (Southeast - Athens) was awarded \$299k to support the development of a dual-acting small molecule for the treatment of type 1 diabetes.
- **Clarigent Health** (Southwest - Mason) was awarded \$459k to improve the performance of an AI-enabled clinical decision support tool for detecting suicidal risk and other mental health concerns.

- **Global Research & Development** (Central - Columbus) was awarded \$1.5M to develop a method for delivery of on-demand, medical-grade oxygen for military medical needs.
- **Innogized Technologies** (Northeast - Chesterland) was awarded \$982k supporting the development of advanced in-home technologies that enable safer and optimally nurturing infant sleep environments.
- **Integrated Sensors** (Northwest - Toledo) was awarded \$562k toward a novel form of radiation therapy that promises large sparing of normal tissues in cancer treatment while showing no tumor sparing.
- **OsteoDx** (Southeast – Athens) was awarded \$1.2M to continue developing and validating a novel osteoporosis-related diagnostic device providing direct information about bone strength and quality.
- **P2D Bioscience** (Southwest - Cincinnati) was awarded \$470k to develop a first-in-class orally bioavailable treatment for Alzheimer's disease.
- **RAM Medical Innovations** (Western - Springfield) was awarded \$1.1M supporting the development of a new arterial sheath for stroke and other neurovascular interventions.
- **SREE Medical Systems** (Northeast - Cleveland) was awarded \$1.3M toward next-generation radio frequency coils for magnetic resonance imaging.
- **You Tune Hearing Protection** (Western - Oakwood) was awarded \$686k to develop advanced earplugs to prevent tinnitus and hearing loss, the highest service-connected disability in the U.S. military.

SBIR/SSTR funding for health innovation is rarely sufficient to sustain the entire development process, let alone commercialization, but it can move the discovery process forward and begin the development process. The remaining stages require private sector partnerships and investments much greater than at the early R&D stage. Without SBIR/STTR funding, many potential health innovations won't make it to commercialization.

Innovative Ohio small businesses depend on the SBIR/STTR programs to address the research needs of our federal agencies. As they move their innovations forward, they grow their businesses, create jobs, and contribute to Ohio's economy. A Defense Department assessment showed the SBIR/STTR programs have generated a 22:1 return for every federal dollar spent. A study by the National Academy of Sciences found a 50-60% commercialization rate for SBIR/STTR investments - a win-win for the U.S. economy and taxpayers.

Allowing even a short disruption of these programs could have negative consequences for high-tech small businesses that thrive on stability and predictability to budget and plan for the future - especially as we all work together to emerge from the COVID-19 pandemic and overcome the economic challenges it triggered.

Thank you for your consideration and for all you do to support the people of Ohio.

Sincerely,

BioOhio - Eddie Pauline, President & CEO
3Bar Biologics - Bruce Caldwell, CEO & Founder
ACE Medical Company - Alexander Ebner,
 President

Alloy Development Co. - Patrick Longo, President
 & CEO
Amplicore - C. James Lin, PhD, President & CEO
Andelyn Biosciences - Wade Macedone, Chief
 Operations Officer

AndHealth - Erica Conroy, SVP, Employer Partnerships
Anemed - Jeffrey Lietzke, CEO
Armatus Bio - Michael Triplett, Ph.D., Co-Founder & CEO
AtriCure - Sam Privitera, CTO
BDSRA Foundation - Morgan DeBoth, VP; Support & Advocacy
Brixey & Meyer - Jeff Bruner, CMA, Shareholder
Buderer Drug Company - Matthew Buderer, R.Ph., FIACP, Director of Research and Development
Capture Collective - Stephanie Sookram, Executive Administrator
Cardinal Health - Aklilu Tedla, VP/GM, Insights & Engagement, Regulatory Sciences, Advanced Therapy Solutions
Cincinnati Children's Hospital - Abram Gordon, JD, Vice President, Innovation Ventures
CincyTech - Mike Venerable, CEO & Managing Director
Clarametix Biosciences - David Richards, CEO
Cleveland Clinic - Catherine Teringo, Program Manager II, Innovations & Technology Development
CMC Pharmaceuticals - Mike Radomsky, President
CMD MedTech - Chad Gibson, RAC, Managing Partner
CollaMedix - Subba Shankar, Ph.D., Chief Technology Officer
Columbus Partnership - Kenny McDonald, President & CEO
Convelo Therapeutics - Brad Lang, Vice President of Research, Biology Team Lead
Crystal Diagnostics - Gary D. Niehaus, Ph.D., Chief Scientist
CTI Clinical Trial & Consulting Services - Timothy Schroeder, Chairman & CEO
Danis - Jamie Stevenson, Vice President
Dupler Office - Brandon Dupler, Principal
Enable Injections - Michael Hooven, President & CEO

Forge Biologics - Erandi De Silva, Ph.D., Co-Founder & Senior Vice President of Product Development
Greater Cleveland Partnership - Baiju Shah, President & CEO
Groh Consulting - Margaret Groh, Ph.D., Principal
Haima Therapeutics - Michael Bruckman, PhD, CEO
INFINITY Angioplasty Balloon Co. - Gary Smith, CEO
Insperty - Tim Redman, Business Performance Advisor
JALEX Medical - Jennifer Palinchik, President
JumpStart - Ray Leach, CEO
Kurome Therapeutics - Jan Rosenbaum, Ph.D., President & CEO, Chief Scientific Officer
Matrix F.T. - Teryn Wolfe, Vice President of Corporate Development
Matrix Medical Devices - Stephanie Harrington, Founder and Principal Consultant
Miami University - Randi Malcolm Thomas, Esq., Vice President of ASPIRE (Advancing Strategy, Partnerships, Institutional Relations, & Economy)
Mix Talent - K.C. McAllister, Head of Strategy
MJM Management Specialists - Michael Gaul, President
ML Consult - Dr. Marc Lemaitre, Consultant, Pharmaceutical Development
N8 Medical - Glenn Brunner, VP, Research & Development
NAMSA - Michelle Leonard, VP of Global Human Resources & Integration
Nationwide Children's Hospital - Matthew McFarland, RPh, Ph.D., Vice President of Commercialization and Industry Relations
Nerve - Stephanie Harrington, Chief Clinical & Regulatory Officer
Neuros Medical - Thomas Wilder, CEO
The Ohio Academy of Science - Michael Woytek, Executive Director
The Ohio State University Wexner Medical Center - Jennifer Dauer, Chief Strategy and Transformation Officer

Ohio University - Stacy Strauss, Director, Ohio University Innovation Center
Olon Ricerca Bioscience - Robert Poe, MBA, CEO
Otterbein University - Dr. John Comerford, President
Oxyrase - James Copeland, Ph.D., President
Precision Environments - Tim VonderHaar, President
Protein Capture Science - Izabela Gierach, Ph.D., MBA, CEO, Co-Founder
Q Laboratories - Jeff Rowe, President & CEO
Quidel - Shawn Mallett, Senior Director, Manufacturing Operations & Site Leader
Remington-Davis - Hamish Baird, President

Rev1 Ventures - Tom Walker, President & CEO
Shimadzu Scientific Instruments - Heather Juzwa, Senior Field Sales Engineer
Soldiers to Sawyers - Chris Werronen, CEO
STAQ Pharma - Joe Bagan, CEO
State and Federal Communications - Elizabeth Bartz, President & CEO
Taylor Strategy Partners (a Syneos Health company) - Mike Gamble, President
UH Ventures - David Sylvan, President
Walsh University - Daniel Passerini, Ph.D., Executive Director of Cross-Enterprise Operations

Ohio Supports the SBIR/STTR

